Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04791514
Status:
TERMINATED
Last Update Posted:
2023-09-22
First Post:
2021-03-08
Brief Title:
A Study of Treprostinil Palmitil Inhalation Powder TPIP In Pulmonary Arterial Hypertension PAH
Sponsor:
Insmed Incorporated
Organization:
Insmed Incorporated
Study Overview
Official Title:
An Open-Label Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
Status:
TERMINATED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low enrolment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder TPIP in participants with pulmonary arterial hypertension PAH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None